三阴性乳腺癌分子分型与异质性的研究进展

Research progress on molecular classification and heterogeneity of triple-negative breast cancer

三阴性乳腺癌（triple-negative breast cancer,TNBC）是指ER、PR及HER-2均为阴性的乳腺癌,占乳腺癌15%~20%。随着基因组学的发展,乳腺癌的分型已不仅局限于基于免疫组织化学的传统分子分型,其中TNBC也被认为是一类异质性疾病,其异质性在分子水平、病理学以及临床特征上也各不相同。因此,对TNBC进一步行分子分型将为靶向治疗带来极大获益,但TNBC分子分型尚无被广泛认可的统一标准,现就最新相关研究做一综述。

Triple- negative breast cancer（TNBC） is defined by the lack of estrogen receptors（ERs） and progesterone receptors（PRs）and by the human epidermal growth factor receptor 2（HER2）-negative status. TNBC accounts for 15% to 20% of breast cancer cases.Genomic profiling studies have demonstrated that breast cancer heterogeneity extends beyond the classic immunohistochemistry（IHC）- based divisions. TNBC is also a heterogeneous disease on the molecular level, as well as on the pathologic and clinical levels.Thus, the molecular subclassification of TNBC will be of considerable value to the development of targeted therapies. However, no widely recognized standard for the molecular classification of TNBC exists. This review provides a brief summary on the latest research on TNBC.